A phase I/II, open-label, multicenter study to evaluate the safety, pharmacokinetics, pharmacodynamics, and efficacy of HB0036 in patients with advanced solid tumors.

View Full Paper

Ask AI

Bookmark

Authors

Discussion

Phase I/II trial evaluates HB0036's safety and efficacy in advanced solid tumors, indicating promising outcomes.

HB0036 demonstrated an acceptable safety profile and showed early anti-tumor activity, suggesting potential as a treatment.
Out of 19 patients enrolled, 68.4% experienced treatment-related adverse events without dose-related severity.
Dose escalation utilized a 3+3 design to determine safety, tolerability, and maximum tolerated dose for HB0036 therapy in patients with advanced malignancies and prior treatments were extensive with a median of 2 lines of therapy per participant. The study findings support further investigation into HB0036 both as monotherapy and in combination with other agents.

Sun et al. (2024) studied this question.

View Full Paper

Ask AI

Bookmark

View Full Paper

Ask AI

Bookmark

Authors

Phase I/II trial evaluates HB0036's safety and efficacy in advanced solid tumors, indicating promising outcomes.

HB0036 demonstrated an acceptable safety profile and showed early anti-tumor activity, suggesting potential as a treatment.
Out of 19 patients enrolled, 68.4% experienced treatment-related adverse events without dose-related severity.
Dose escalation utilized a 3+3 design to determine safety, tolerability, and maximum tolerated dose for HB0036 therapy in patients with advanced malignancies and prior treatments were extensive with a median of 2 lines of therapy per participant. The study findings support further investigation into HB0036 both as monotherapy and in combination with other agents.

Sun et al. (2024) studied this question.

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

View Full Paper

Ask AI

Bookmark